Open for Recruitment
Phase II: Protocol Number AGITG AG1013GST
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST).
Phase III: Boston CanStem303C CRC
A phase III study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in adult patients with previously Treated Metastatic Colorectal Cancer (CRC)
Phase III: BR.31
A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer.
Phase II/III: Protocol Number 1199.93 LUME
Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemtrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma.
Phase II: Protocol Number MM-121-01-02-09
A phase 2 study of MM-121 in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer.
Phase III: Protocol Number BPI-2358-103 (Beyond Spring)
Randomized blinded phase 3 assessment of second-or third line chemotherapy with docetaxel + plinabulin compared to docetaxel + placebo in patients with advanced non-small cell lung cancer with at least 1 large lung lesion.
Phase I+II: Protocol ABBVIE-M14-361
A phase 1 dose escalation and phase 2 randomized double-blind study of veliparib in combination with carboplatin and etoposide as a therapy of treatment-naïve extensive stage disease small cell lung cancer incorporating administrative change 1 and amendments 1, 2 and 3.
BMS CA209234 (NIVOPASS)
Pattern of use and safety/effectiveness of nivolumab in routine oncology practice.
Phase I: Protocol Number HMPL-523 Hutchision
A phase I, open-label, dose-escalation study of the safety and pharmacokinetics of HMPL-523 in patients with relapsed or refractory Hematologic Malignancies
Protocol Number GS-US-313-1580
Dose optimization study of idelalisib in follicular lymphoma and small lymphocytic lymphoma.
Phase III: Protocol Number 20130109
A randomized, double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with rituximab in subjects with CD20 positive B-cell Non-Hodgkin Lymphoma (NHL)
Phase III: Protocol Number HALO-109-301
A phase 3, randomized, double-blind, placebo-controlled, multicentre study of PEGylated recombinant human hyaluronidase (PEGPH20) in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma
Protocol CO-338-052 (TRITON2):
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
PHASE I: AbbVie M15-862
A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects With Advanced Solid Tumors
Hutchison 2015-453-00AU1: (First in Human)
A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients with Advanced Solid Malignancies.
Ongoing (Not Recruiting)
Phase III: EMBRACA
A phase 3, open-label, randomized, parallel, 2-arm, multi-center study of talazoparib (BMN 673) versus physician’s choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer, who have received prior chemotherapy regimens for metastatic disease.
Phase III: Protocol WO29522 IMpassion130
A phase III, multicenter, randomized, placebo-controlled study of MPDL3280A (anti−PD-L1 antibody) in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for patients with previously untreated metastatic triple-negative breast cancer.
Phase II Extension Study : Protocol TDM4529g/BO25430
This is a global, multicenter, open-label extension study. Patients receiving single-agent T-DM1 or combination T-DM1 administered in combination with paclitaxel or with pertuzumab ± paclitaxel in a Genentech/Roche-sponsored study who completed the parent study or who continue to receive study drug(s) at the time of the parent study closure are eligible for continued treatment on this protocol.
Phase II: Protocol GO29689
A phase II, open-label, randomized study of GDC-0810 versus fulvestrant in postmenopausal women with advanced or metastatic ER+ /HER2 − breast cancer resistant to aromatase inhibitor therapy.
Phase III: Protocol D5164C00001 (ADAURA)
A phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus placebo in patients with epidermal growth factor receptor mutation positive stage IB-IIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy.
Phase II: Protocol Number HM-EMSI-202
A single-arm, open-label, phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
Phase II: AVEO-AV-299-14-206
A phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.
Phase III: Protocol Number GO29438 (ImPower)
A phase III, open-label, randomized study of atezolizumab (mpdl3280a, anti−pd-l1 antibody) in combination with carboplatin or cisplatin+pemetrexed compared with carboplatin or cisplatin+pemetrexed in patients who are chemotherapy-naive and have stage iv non-squamous non−small cell lung cancer.
Phase III: Protocol Number GS-US-296-1080
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Phase III: Protocol Number BBI608-336
A phase III randomized, double-blind, placebo-controlled clinical trial of BBI608 plus weekly paclitaxel vs. placebo plus weekly paclitaxel in adult patients with advanced, previously treated gastric and gastro-esophageal junction adenocarcinoma.
Phase III: Protocol Number GO30182
A phase III, open-label, multicentre, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal cancer.
Phase II: BL.12
A multicentre randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen.